Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2567792 | Pulmonary Pharmacology & Therapeutics | 2009 | 6 Pages |
Ambient ozone has been linked to the worsening of symptoms of patients with obstructive diseases such as chronic obstructive pulmonary disease (COPD) and asthma. We investigated the role of cathepsin S on ozone-induced airway hyperresponsiveness (AHR) and inflammation, using the selective cathepsin S inhibitor, Compound A. Balb/c mice were exposed to ozone at a concentration of 3 ppm or air for 3 h, following administration by gavage of Compound A or vehicle. Bronchoalveolar lavage (BAL) was performed 3 h and 20–24 h following exposure, AHR was measured at 20–24 h only. Ozone exposure, compared to air exposure increased BAL cathepsin S levels, AHR and BAL inflammatory cells. Compound A (30 mg kg−1 p.o.) dosing compared to vehicle dosing inhibited ozone-induced AHR (−log PC100 vehicle: −0.70 ± 0.12, n = 8 vs. cathepsin S inhibitor: −1.30 ± 0.06, P < 0.001, n = 8) at 20–24 h and BAL neutrophilia at 3 h and 20–24 h (P < 0.05, n = 6). Ozone exposure increased levels of BAL cytokines IL-6, TNF-α and IFN-γ. Compound A reduced IL-6 at 3 h and 20–24 h (P < 0.05, n = 5) and TNF-α, at 20–24 h (P < 0.05, n = 6). These data indicate an important role for cathepsin S in the regulation of ozone-induced AHR and neutrophil cell recruitment and suggest that cathepsin S may be a target in the treatment of oxidative stress-induced AHR and inflammation.